Kiniksa Pharmaceuticals International, plc Balance Sheet
KNSA / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
Kiniksa Pharmaceuticals International, plc had $764M in total assets and $568M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M | $114.0M | $46.9M | $72.0M | $45.6M |
| Accounts Receivable | $15.6M | $41.7M | $21.3M | $12.7M | $4.0M | - | - | - | - |
| Inventory | $54.9M | $26.4M | $31.1M | $21.6M | $3.7M | - | - | - | - |
| Current Assets | $527.2M | $331.8M | $276.3M | $243.1M | $196.4M | $333.2M | $241.6M | $313.8M | $47.1M |
| PP&E (Net) | $1.9M | $662.0K | $734.0K | $1.7M | $2.8M | $4.1M | $6.4M | $6.4M | $125.0K |
| Total Assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M | $349.5M | $254.5M | $322.0M | $47.5M |
| Current Liabilities | $139.2M | $100.6M | $63.7M | $47.1M | $44.8M | $31.8M | $27.8M | $42.6M | $17.4M |
| Shareholders' Equity | $567.6M | $438.4M | $438.8M | $396.1M | $225.4M | $311.9M | $225.4M | $279.3M | -$89.7M |